Nuvation Bio Inc. Class A Common Stock vs ProShares UltraPro QQQ ETF — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.04 (market cap $1.74B), while ProShares UltraPro QQQ ETF trades at $81.07 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 22.3× Nuvation Bio Inc. Class A Common Stock's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| NUVB | TQQQ | |
|---|---|---|
Market Cap | $1.74B | $38.74B |
Volume | 9,289,619 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.54 | $87.22 |
52-Week Low | $3.41 | $37.89 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.33B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TQQQ trades at $80.67, down 3.5% in the last session amid mixed technical signals. The ETF maintains a bullish overall technical rating with strong moving average support but faces neutral oscillators. Recent news highlights significant hidden costs beyond the stated 0.82% expense ratio, including financing charges that impact returns. Institutional activity shows mixed positioning with some firms reducing stakes while others add exposure.
Outlook remains volatile given TQQQ's 3x leveraged structure, which amplifies both gains and losses. The ETF faces headwinds from volatility decay and hidden costs, though AI-driven tech growth provides underlying support. Key risks include amplified drawdowns during market corrections and structural costs that erode long-term performance versus the underlying index.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →